Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta

Multiple Sclerosis

Volumn 14, Issue 2, 2008, Pages 212-218

  Farrell, Rachal ^a,b,c   Kapoor, R ^a   Leary, S ^a   Rudge, P ^a   Thompson, A J ^a   Miller, D H ^a   Giovannoni, G ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

binding antibody; interferon beta; Luciferase assay; Multiple Sclerosis; neutralizing antibody

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON ANTIBODY; INTERFERON BETA SERINE; LUCIFERASE; MITOXANTRONE; NEUTRALIZING ANTIBODY; PARACETAMOL;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; FREQUENCY ANALYSIS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SKIN MANIFESTATION;

ADULT; AGED; ANTIBODIES; ANTIBODY SPECIFICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LUCIFERASES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 43149085573     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458507082066     Document Type: Article

References (27)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43 (4): 655-61.
2. Paty DW, Li DK Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43 (4): 662-67.
3. PRISMS Study Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56 (12): 1628-36.
4. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352 (9139): 1498-1504.
5. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999; 53 (4): 679-86.
6. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47 (4): 889-94.
7. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39 (3): 285-94.
8. Perini P., Facchinetti A., Bulian P., Massaro AR, Pascalis DD, Bertolotto A. et al. Interferon-beta (INFbeta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001; 12 (1): 56-61.
9. Ross C., Clemmesen KM, Svenson M., Sorensen PS, Koch-Henriksen N., Skovgaard GL et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48 (5): 706-12.
10. Panitch H., Goodin DS, Francis G., Chang P., Coyle PK, O'Connor P. et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59 (10): 1496-1506.
11. Clanet M., Radue EW, Kappos L., Hartung HP, Hohlfeld R., Sandberg-Wollheim M. et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59 (10): 1507-17.
12. Sorensen PS, Ross C., Clemmesen KM, Bendtzen K., Frederiksen JL, Jensen K. et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362 (9391): 1184-91.
13. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multi-centre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352 (9139): 1491-7.
14. Sorensen PS, Koch-Henriksen N., Ross C., Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65 (1): 33-39.
15. Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology 2003; 61 (9 Suppl 5): S13-S17.
16. Hartung HP, Munschauer FE, III. Assessment and management of neutralizing antibodies in patients with multiple sclerosis. J Neurol 2004; 251 (Suppl 2): 1140-1142.
17. Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001; 58 (8): 1297-98.
18. Francis GS, Rice GP, Alsop JC Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65 (1): 48-55.
19. Kappos L., Clanet M., Sandberg-Wollheim M., Radue EW, Hartung HP, Hohlfeld R. et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65 (1): 40-7.
20. Pachner AR An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003; 61 (10): 1444-46.
21. Brickelmaier M., Hochman PS, Baciu R., Chao B., Cuervo JH, Whitty A. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta. J Immunol Methods 1999; 227 (1-2): 121-35.
22. Grossberg SE, Kawade Y., Kohase M., Yokoyama H., Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001; 21 (9): 729-42.
23. Grossberg SE, Kawade Y., Kohase M., Klein JP The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21 (9): 743-55.
24. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986; 119: 558-73.
25. Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler 2000; 6 (2): 86-90.
26. Giovannoni G., Goodman A. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 2005; 65 (1): 6-8.
27. Sorensen PS, Deisenhammer F., Duda P., Hohlfeld R., Myhr KM, Palace J. et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12 (11): 817-27.